Custom DNA test

Asper Biotech logo  

CompanyGenetic testingAPEX TechnologyDNA Shipping / ?Quick Links

   
Asper Biotech is a genetic testing company with an established set of robust and efficient DNA tests. Asper is also a reliable partner for the scientific and commercial communities in their custom genotyping projects.
  

 

 

Eesti keel

genetic disease, genetic engineering,  custom chip design, genotyping services, human  high-throughput genotyping, microarray design, genome, Apex,  development, arrayed primer extension, SNP,  genomics, genetic testing services, SNP tests, DNA chip, arrayed primer extension, microarray scanner, p53,  drug development,  diagnostics, personalized  treatment, human medicine, SNP, biotechnology, technology transfer, gene, DNA test      
    04.2008 The Ashkenazi Jewish diseases test updated

The chip has been updated by adding 8 new mutations to the test. The current test version covers 77 mutations from 22 different genes related to Cystic Fibrosis, Tay Sachs, Bloom -, Canavan -, Niemann-Pick A syndrome, Familian dysautonomia, Torsion dystonia, Mucolipidosis IV, Fanconi Anemia, Factor XI deficiency, Glycogen storage disease, Marple Syrup Urine disease, Nonsyndromic sensorineural hearing loss, Familial mediterranean fever, Alpha 1-anti-trypsin Deficiency, Nemaline Myopathy, Usher Syndrome Type 1F, Familial hyperinsulinemia, Familial Hypercholesterolemia, Gaucher disease and Lipoamide Dehydrogenase Deficiency, Gaucher disease and Lipoamide Dehydrogenase Deficiency.


    04.2008

New publication co-authored by Asper scientist was published:

Genotyping microarray as a novel approach for the detection of ATP7B gene mutations in patients with Wilson disease
Gojova L., Jansova E., Külm M., Pouchla S., Kozak L.
Clinical Genetics 2008: 73: 441–452


    04.2008 Asper Ophthalmics will be represented at the 15th Retina International World Congress "Research into practice" with its exhibition stand. 

The congress will be held in Finlandia Hall, Helsinki, Finland on 4th-5th July, 2008. Asper welcomes all existing partners and everyone interested in collaboration with Asper to attend the congress and meet in its booth.


    03.2008

Leber congenital amaurosis chip updated

44 new mutations and 1 new gene (LCA5) can be analyzed by  LCA  chip. Currently the test can be used for the screening of 495 mutations in 12 genes: AIPL1, CRB1, CRX, GUCY2D, LRAT, MERTK, CEP290, RDH12, RPGRIP1, RPE65, LCA5 and TULP1.



     02.2008 Corneal dystrophy assay updated
  
Corneal dystrophy chip has been updated by adding 68 new mutations to the test. The current test version covers 297 different mutations from 12 genes:
COL8A2, TGFBI, VSX1, CHST6, KRT3, KRT12, GSN, TACSTD2, CYP4V2, SOD1, TCF8/ZEB1, SLC4A11. 


    02.2008 Asper Ophthalmics will be represented at the ARVO 2008 - Eyes on Innovation - in Fort Lauderdale, Florida, USA, on April 27-April 30.
 
As last three years, Asper will be represented at the meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2008. The meeting will be held in Broward County Convention Center, Fort Lauderdale, Florida, USA on April 27 - April 30. Asper welcomes all existing partners and everyone interested in collaboration with Asper to attend the conference and meet in its booth #715.


    02.2008 Asper Biotech invites all interested to its booth #444 at the 40th European Human Genetics Conference - ESHG 2008 in Barcelona, Spain, 31 May - 3 June.
 
Asper will be represented at the 40th European Human Genetics Conference - ESHG 2008. The conference will be held in Center Convencions Internacional Barcelona - CCIB, Barcelona, Spain on May 31-June 3. Asper welcomes all existing partners and everyone interested in collaboration with Asper to attend the conference and meet in its booth #444. 

 

    11.2007
The Estonian Biocentre (EBC) and Asper Biotech Ltd signed a licencing agreement that authorises Asper Biotech to use „Analysis Method of Risk Alleles for estimation of predisposition of Inheritant Breast and Ovarian Cancer“ which has been recognised as a utility model.

The utility model describes recently discovered risk alleles in the Estonian population as well as their analysis, together with the risk alleles of breast and ovarian cancer, which have already been described in public databases.

Asper Biotech Ltd is a spin-off company of the Estonian Biocentre and Tartu University, established in 1999 and specialised in genetic test development and offering the service of DNA analysis. The establishment’s services are available in over 30 countries, being the biggest exporter in the Estonian sector of biotechnology.

The Estonian Biocentre (EBC) was established in 1986 by the decree of the government as a state owned scientific and educational institution. The main research direction of the EBC lies in the field of molecular medicine and is linked to biotechnology.
 

 

   Try Genorama Microarray slides  

GENETIC TESTS

   Thalassemia testing

   Hereditary Hearing Loss
   
testing

   Cystic Fibrosis testing

   DNA repair testing

   Ashkenazi Jewish (AJ)
    diseases testing

   Stargardt disease, age
   
related macular 
    dystrophy, cone-rod
    dystrophy testing

   Usher syndrome testing
 
   Leber congenital
    amaurosis (LCA) genetic
    testing        
 
 
  Autosomal recessive
   
retinitis pigmentosa 
    (AR-RP) genetic testing

   Autosomal dominant
   
retinitis pigmentosa 
    (AD-RP) genetic testing
  
   Bardet Biedl syndrome
    (BBS) genetic testing

  
Autosomal dominant
   
optic atrophy testing 

  
Corneal dystrophy
   
testing 

   Congenital stationary
   
night blindness 
    genetic testing

    Vitelliform macular
    dystrophy testing

  

The summary 
of all tests


MICROARRAY SLIDES

   Genorama® SAL

   Genorama® SA
  

 

Spotting ordering FORM

Sample submission FORM

  

    
  
 

ISO 9001 quality standard